Edition:
United Kingdom

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Global Select Market

13.74USD
22 Jun 2018
Change (% chg)

$-0.11 (-0.79%)
Prev Close
$13.85
Open
$13.83
Day's High
$13.99
Day's Low
$13.35
Volume
5,590,930
Avg. Vol
325,901
52-wk High
$15.59
52-wk Low
$5.04

Chart for

About

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $358.81
Shares Outstanding(Mil.): 43.76
Dividend: --
Yield (%): --

Financials

  CBAY.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -1.06 -- --
ROI: -182.71 2.00 14.38
ROE: -308.78 3.49 16.08

BRIEF-CymaBay Therapeutics Q1 Loss Per Share $0.32

* CYMABAY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 May 2018

BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis

* CYMABAY THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS

08 May 2018

BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis

* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESS™ 2018

11 Apr 2018

BRIEF-Cymabay Reports Q4 Loss Per Share $0.11

* CYMABAY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

15 Mar 2018

BRIEF-CymaBay Announces Proposed Public Offering Of Common Stock

* CYMABAY THERAPEUTICS INC - ‍ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF SELADELPAR​ Source text for Eikon: Further company coverage:

29 Jan 2018

BRIEF-Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America

* CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study

* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln

* CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2pRWkXa) Further company coverage:

29 Dec 2017

Earnings vs. Estimates